Description de l'entreprise
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Osamu Okuda |
| Conseil d'administration |
| Toshiaki Itagaki |
| Conseil de surveillance |
| Dr. Osamu Okuda, Dr. Hisafumi Yamada, Toshiaki Itagaki, Dr. Mariko Y Momoi, Dr. Fumio Tateishi, Hideo Teramoto, Dr. Christoph Franz, Dr. James H. Sabry, Teresa A. Graham |
Données de l'entreprise
| Nom: |
Chugai Pharmaceutical Co., Ltd. |
| Adresse: |
1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku,Tokyo 103-8324 |
| Téléphone: |
+81-(0)3-3281-6611 |
| Fax: |
+81-(0)3-3281-6607 |
| Courriel: |
-
|
| Internet: |
https://www.chugai-pharm.co.jp/english/index.html |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
- |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
+81-(0)3-3273-0554 |
| IR-Fax: |
+81-(0)3-3281-6607 |
| E-mail IR: |
-
|
